Literature DB >> 11181437

G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype.

E C Akam1, R A Challiss, S R Nahorski.   

Abstract

1. Profiles of G protein activation have been assessed using a [35S]-GTPgammaS binding/immunoprecipitation strategy in Chinese hamster ovary cells expressing either M1, M2, M3 or M4 muscarinic acetylcholine (mACh) receptor subtypes, where expression levels of M1 and M3, or M2 and M4 receptors were approximately equal. 2. Maximal [35S]-GTPgammaS binding to G(q/11)alpha stimulated by M1/M3 receptors, or G(i1-3)alpha stimulated by M2/M4 receptors occurred within approximately 2 min of agonist addition. The increases in G(q/11)alpha-[35S]-GTPgammaS binding after M1 and M3 receptor stimulation differed substantially, with M1 receptors causing a 2-3 fold greater increase in [35S]-GTPgammaS binding and requiring 5 fold lower concentrations of methacholine to stimulate a half-maximal response. 3. Comparison of M2 and M4 receptor-mediated G(i1-3)alpha-[35S]-GTPgammaS binding also revealed differences, with M2 receptors causing a greater increase in G(i1-3)alpha activation and requiring 10 fold lower concentrations of methacholine to stimulate a half-maximal response. 4. Comparison of methacholine- and pilocarpine-mediated effects revealed that the latter partial agonist is more effective in activating G(i3)alpha compared to G(i1/2)alpha for both M2 and M4 receptors. More marked agonist/partial agonist differences were observed with respect to M1/M3-mediated stimulations of G(q/11)alpha- and G(i1-3)alpha-[35S]-GTPgammaS binding. Whereas coupling to these Galpha subclasses decreased proportionately for M1 receptor stimulation by these agonists, pilocarpine possesses a greater intrinsic activity at M3 receptors for G(i)alpha versus G(q/11)alpha activation. 5. These data demonstrate that mACh receptor subtype and the nature of the agonist used govern the repertoire of G proteins activated. They also provide insights into how the diversity of coupling can be pharmacologically exploited, and provide a basis for a better understanding of how multiple receptor subtypes can be differentially regulated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181437      PMCID: PMC1572629          DOI: 10.1038/sj.bjp.0703892

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Persistent membrane association of activated and depalmitoylated G protein alpha subunits.

Authors:  C Huang; J A Duncan; A G Gilman; S M Mumby
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

2.  A single receptor encoded by vzg-1/lpA1/edg-2 couples to G proteins and mediates multiple cellular responses to lysophosphatidic acid.

Authors:  N Fukushima; Y Kimura; J Chun
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

3.  Determination of [35S]guanosine-5'-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay.

Authors:  N W DeLapp; J H McKinzie; B D Sawyer; A Vandergriff; J Falcone; D McClure; C C Felder
Journal:  J Pharmacol Exp Ther       Date:  1999-05       Impact factor: 4.030

Review 4.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

5.  Agonist-induced translocation of Gq/11alpha immunoreactivity directly from plasma membrane in MDCK cells.

Authors:  J M Arthur; G P Collinsworth; T W Gettys; J R Raymond
Journal:  Am J Physiol       Date:  1999-04

6.  Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I.

Authors:  N T Burford; L M Tolbert; W Sadee
Journal:  Eur J Pharmacol       Date:  1998-01-19       Impact factor: 4.432

7.  Differential coupling of m1, m2 and m3 muscarinic receptor subtypes to inositol 1,4,5-trisphosphate and adenosine 3',5'-cyclic monophosphate accumulation in Chinese hamster ovary cells.

Authors:  N T Burford; A B Tobin; S R Nahorski
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

8.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus.

Authors:  K A Berg; S Maayani; J Goldfarb; C Scaramellini; P Leff; W P Clarke
Journal:  Mol Pharmacol       Date:  1998-07       Impact factor: 4.436

9.  Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists.

Authors:  M H Richards; P L van Giersbergen
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

10.  Coupling of muscarinic m1, m2 and m3 acetylcholine receptors, expressed in Chinese hamster ovary cells, to pertussis toxin-sensitive/insensitive guanine nucleotide-binding proteins.

Authors:  N T Burford; A B Tobin; S R Nahorski
Journal:  Eur J Pharmacol       Date:  1995-04-28       Impact factor: 4.432

View more
  22 in total

1.  Growth inhibition by the muscarinic M(3) acetylcholine receptor: evidence for p21(Cip1/Waf1) involvement in G(1) arrest.

Authors:  Drew Burdon; Rajnikant Patel; R A John Challiss; Jonathan L Blank
Journal:  Biochem J       Date:  2002-10-15       Impact factor: 3.857

2.  Structural aspects of M₃ muscarinic acetylcholine receptor dimer formation and activation.

Authors:  Jianxin Hu; Doreen Thor; Yaru Zhou; Tong Liu; Yan Wang; Sara M McMillin; Rajendra Mistry; R A John Challiss; Stefano Costanzi; Jürgen Wess
Journal:  FASEB J       Date:  2011-10-26       Impact factor: 5.191

Review 3.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

5.  Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor.

Authors:  Karen Coopman; Yan Huang; Neil Johnston; Sophie J Bradley; Graeme F Wilkinson; Gary B Willars
Journal:  J Pharmacol Exp Ther       Date:  2010-05-27       Impact factor: 4.030

6.  An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins.

Authors:  Rajendra Mistry; Mark R Dowling; R A John Challiss
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

7.  Meiotic resumption in response to luteinizing hormone is independent of a Gi family G protein or calcium in the mouse oocyte.

Authors:  Lisa M Mehlmann; Rebecca R Kalinowski; Lavinia F Ross; Albert F Parlow; Erik L Hewlett; Laurinda A Jaffe
Journal:  Dev Biol       Date:  2006-08-05       Impact factor: 3.582

8.  Differential Rho-kinase dependency of full and partial muscarinic receptor agonists in airway smooth muscle contraction.

Authors:  Dedmer Schaafsma; Mark Boterman; Anne-Margreet de Jong; Iris Hovens; Jelte-Maarten Penninks; S Adriaan Nelemans; Herman Meurs; Johan Zaagsma
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

9.  Unconventional homologous internalization of the angiotensin II type-1 receptor induced by G-protein-independent signals.

Authors:  Ying-Hong Feng; Yaxian Ding; Shuo Ren; Lingyin Zhou; Chuan Xu; Sadashiva S Karnik
Journal:  Hypertension       Date:  2005-07-05       Impact factor: 10.190

Review 10.  Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs.

Authors:  Gregory J Digby; P Jeffrey Conn; Craig W Lindsley
Journal:  Curr Opin Drug Discov Devel       Date:  2010-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.